SB776 establishes a temporary Workgroup to Study the Rise in Adverse Decisions in Maryland’s health care system. The workgroup is charged with examining how often adverse decisions occur across all health payers, comparing those decisions to total claims processed, reviewing enrollee counts, and collecting diagnostic, procedure, network adequacy, grievance, complaint, and appeal information. It must also consider clinical outcome measures such as NCQA ratings and CMS star ratings, and use that information to identify trends and possible causes of increased denials or other adverse determinations.
The workgroup is directed to make recommendations for improving State reporting requirements and standardizing terminology and processes related to adverse decisions, including definitions of medical service categories, health settings, medical necessity, and adverse decisions themselves. It must also recommend a standardized method for categorizing adverse decisions and prior authorization denials, as well as a consistent process for reporting grievances and appeals. In addition, the workgroup is expected to develop strategies to reduce the number of adverse decisions and propose legislation to address the issue across all payers.
The bill affects Maryland health care reporting and oversight law by creating a new, time-limited advisory body rather than immediately changing substantive coverage or claims rules. It brings together legislators, state regulators, hospital and insurer representatives, providers, a patient advocate, and other health system stakeholders, with staffing provided jointly by the Health Services Cost Review Commission and the Maryland Insurance Administration. The workgroup must report its findings and recommendations to the Senate Finance Committee and House Health and Government Operations Committee by December 1, 2025, and the act sunsets on June 30, 2026.
The overall sentiment reflected in the voting history is strongly supportive: the bill passed both chambers unanimously, with recorded third-reading votes of 47-0 in the Senate, 131-0 in the House, and 47-0 in a later Senate vote. No committee transcript was provided, so there is no recorded floor or committee debate to indicate opposition. The unanimous votes suggest broad bipartisan agreement that the rise in adverse decisions and prior authorization denials merits study and possible policy response.
The main point of contention implied by the bill’s structure is not whether to study the issue, but how to define, measure, and standardize adverse decisions across different payers and settings. Because the workgroup includes hospitals, insurers, managed care plans, physicians, a pharmacy services provider, a behavioral health provider, a commercial carrier, and a patient advocacy organization, the bill appears designed to balance competing perspectives on utilization management, reporting burdens, patient access, and clinical necessity.
SB776 creates a temporary advisory workgroup within Maryland state government and does not directly amend coverage mandates, claims adjudication rules, or prior authorization standards. Its practical effect is to require state health regulators and stakeholders to collect and analyze data on adverse decisions, then develop recommendations for standardized reporting and possible future legislation. The bill may influence later changes to the Insurance Article, health reporting requirements, and payer oversight if the workgroup’s recommendations are adopted.
The bill appears to have been received very positively, with unanimous passage in both chambers and no recorded dissent in the provided voting history. That level of support suggests legislators broadly agreed that rising adverse decisions in the health care system is a legitimate policy concern worth studying. The absence of committee transcripts limits insight into detailed debate, but the vote totals indicate little visible opposition to creating the workgroup.
The likely areas of contention are technical and policy-oriented rather than partisan: how to define “adverse decisions” and “medical necessity,” whether prior authorization denials should be treated separately, what data payers should be required to report, and how much burden standardized reporting would place on insurers, hospitals, and other providers. Stakeholders such as commercial carriers and managed care plans may be concerned about administrative costs and reporting complexity, while patient advocates and providers may favor greater transparency and stronger protections against denials. The bill’s broad membership suggests an effort to mediate those competing interests through study rather than immediate regulation.